Suppr超能文献

德谷胰岛素与甘精胰岛素起始治疗的2型糖尿病患者的身体成分和心外膜脂肪

Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.

作者信息

Elisha B, Azar M, Taleb N, Bernard S, Iacobellis G, Rabasa-Lhoret R

机构信息

Department of Nutrition, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Institut de Recherches Cliniques de Montréal (IRCM), Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

出版信息

Horm Metab Res. 2016 Jan;48(1):42-7. doi: 10.1055/s-0035-1554688. Epub 2015 Sep 4.

Abstract

The aim of the study was to compare body composition and epicardial fat thickness changes in insulin-naïve inadequately controlled patients with type 2 diabetes following basal insulin initiation with detemir vs. glargine. Six-month, open-label, interventional randomized pilot study was conducted. Dual-energy X-ray absorptiometry and echocardiography were used to estimate the body composition and epicardial fat thickness respectively. Thirty-six patients in the detemir group and 20 in the glargine group completed the study. Study groups baseline characteristics were comparable. At 6 months, for similar glycemic control, those on detemir significantly gained less total weight (0.6±2.5 vs. 4.2±4.1 kg, p=0.004), total fat mass (0.9±2.2 vs. 2.9±2.4 kg, p=0.02), and truncal fat mass (0.8±1.5 vs. 2.1±1.7 kg, p=0.02), with a loss in truncal lean mass (- 0.8±1.9 kg vs. 0.3±1.7 kg; p=0.02). EFT significantly decreased from baseline in both group (detemir - 1.7±0.52-mm, glargine - 1.1±1.6-mm; p<0.05, without significant difference inter-groups). Within the detemir group, epicardial fat thickness change correlated with truncal fat and total fat mass changes (r=0.65, p=0.06 and r=0.60, p=0.07). In conclusion, detemir resulted in less fat mass gain, a trend for a more pronounced epicardial fat thickness reduction when compared with glargine.

摘要

本研究的目的是比较在初治的2型糖尿病控制不佳患者中,起始使用地特胰岛素与甘精胰岛素后身体成分和心外膜脂肪厚度的变化。开展了一项为期6个月的开放标签干预性随机试验研究。分别使用双能X线吸收法和超声心动图来评估身体成分和心外膜脂肪厚度。地特胰岛素组36例患者和甘精胰岛素组20例患者完成了研究。研究组的基线特征具有可比性。在6个月时,在血糖控制相似的情况下,使用地特胰岛素的患者总体重增加显著较少(0.6±2.5 vs. 4.2±4.1 kg,p=0.004),总脂肪量增加较少(0.9±2.2 vs. 2.9±2.4 kg,p=0.02),躯干脂肪量增加较少(0.8±1.5 vs. 2.1±1.7 kg,p=0.02),且躯干瘦体重有所减少(-0.8±1.9 kg vs. 0.3±1.7 kg;p=0.02)。两组的心外膜脂肪厚度均较基线显著降低(地特胰岛素组降低-1.7±0.52 mm,甘精胰岛素组降低-1.1±1.6 mm;p<0.05,组间无显著差异)。在地特胰岛素组中,心外膜脂肪厚度变化与躯干脂肪和总脂肪量变化相关(r=0.65,p=0.06;r=0.60,p=0.07)。总之,与甘精胰岛素相比,地特胰岛素导致脂肪量增加较少,且有心外膜脂肪厚度降低更明显的趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验